Specialities

- Cell culture
- Diagnostics

- High potent (hormones/oncology)
- Hormonal gels
- Hormonal liquids
- Impregnated dressings
- Bottle filling for tablets

Delpharm group offers pharmaceutical products & services which includes tablets naked. It belongs to solid forms category. Semisolids: gelstablets nakedsyrups. Specialties: highly active. Contact us for more information.

Delpharm group offers pharmaceutical services which includes glass prefilled syringes.  Capsules. Contact us for more information.

Delpharm group offers pharmaceutical products & services which includes tablets naked. It belongs to solid forms category. Semisolids: gelstablets nakedsyrups. Specialties: highly active. Contact us for more information.

- Cell culture
- Diagnostics

Delpharm group offers pharmaceutical services which includes capsules. It belongs to solid forms category. Capsules. Contact us for more information.

Delpharm group offers pharmaceutical services which includes sparkling. It belongs to solid forms category. Semisolids: ointment sparkling sachets. Specialties: biotechnology. Contact us for more information.

Delpharm group offers pharmaceutical services which includes coated tablets. It belongs to solid forms category. Semisolids: creamscoated tabletsdrops. Specialties: cytotoxic. Contact us for more information.

Delpharm group offers pharmaceutical services which includes sachets. It belongs to solid forms category. Sachets. Contact us for more information.

Delpharm group offers pharmaceutical services which includes film-coated tablets. It belongs to solid forms category. Semisolids: suppositories film-coated tablets bulbs. Specialties: sterile injectable. Contact us for more information.

Delpharm group offers pharmaceutical services which includes pellets. It belongs to solid forms category. Pellets injectables specialties: barium products. Contact us for more information.

Poznań, Poland, Thursday 15 October 2020 –GSK and Delpharm announced today they have entered into an agreement under which Delpharm will acquire GSK’s Poznań manufacturing facility in Poland.

Delpharm is a European leader in contract manufacturing and development of medicines for pharmaceutical laboratories. It owns 12 manufacturing plants (nine in France, two in Italy and one in Belgium) providing the majority of dosage forms available on the market: tablets, syrups, bottles, vials, etc. Delpharm generates €500m in turnover and is wholly-owned by its management. For more information, visit our website: http://www.delpharm.com/

Delpharm and the Famar Group are pleased to announce the acquisition by Delpharm of 5 manufacturing sites belonging to Famar, in France, Canada and the Netherlands. The transaction signed today covers the French sites located in Orléans (Loiret), L’Aigle (Orne) and Saint-Rémy-sur-Avre (Eure-et-Loire), as well as the Montreal site in Canada and that of Bladel in the Netherlands.

Delpharm is a Worldwide leader in contract manufacturing and development of medicines for pharmaceutical laboratories. It owns 17 manufacturing plants (12 in France, 2 in Italy, 1 in Belgium, 1 in the Netherlands and 1 in Canada) providing the majority of dosage forms available on the market: tablets, syrups, bottles, vials, etc. Delpharm generates €800m in turnover and is wholly-owned by its management. For more information, visit our website: http://www.delpharm.com/